214 Stock Overview
A clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Anebulo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.30 |
| 52 Week High | US$2.88 |
| 52 Week Low | US$1.71 |
| Beta | -0.99 |
| 11 Month Change | -16.67% |
| 3 Month Change | -13.53% |
| 1 Year Change | 7.48% |
| 33 Year Change | -61.02% |
| 5 Year Change | n/a |
| Change since IPO | -60.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 214 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -1.3% | 0.8% |
| 1Y | 7.5% | -17.7% | 6.1% |
Return vs Industry: 214 exceeded the German Pharmaceuticals industry which returned -17.7% over the past year.
Return vs Market: 214 exceeded the German Market which returned 6.1% over the past year.
Price Volatility
| 214 volatility | |
|---|---|
| 214 Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 214's share price has been volatile over the past 3 months.
Volatility Over Time: 214's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 2 | Richie Cunningham | www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company’s lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Fundamentals Summary
| 214 fundamental statistics | |
|---|---|
| Market cap | €57.50m |
| Earnings (TTM) | -€8.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.7x
P/E RatioIs 214 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 214 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.35m |
| Earnings | -US$9.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 214 perform over the long term?
See historical performance and comparison